A217730 Share Price Performance
₩1,353.00
-281.00 (-17.20%)
Price ₩1,353.00
Share Price₩1,353.00
A217730 Community Narratives
There are no narratives available yet.
Recent A217730 News & Updates
No updates
Kangstem Biotech Co., Ltd. Key Details
Last Reported Earnings
Sep 30, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -179.99
- Gross Margin
- 13.91%
- Net Profit Margin
- -78.98%
- Debt/Equity Ratio
- 14.6%
Kangstem Biotech Co., Ltd. Competitors
About A217730
- Founded
- 2010
- Employees
- 97
- CEO
- WebsiteView website
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration. In addition, the company offers stem cell culture media, including KSB-3 kit, a medium for culturing the human mesenchymal stem cell; and cell freezing and thawing platform. Further, it provides pharmaceutical contract manufacturing and development services. Kangstem Biotech Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
South Korean Market Performance
- 7 Days: -2.0%
- 3 Months: 20.9%
- 1 Year: 26.1%
- Year to Date: 28.6%
Over the last 7 days, the market has dropped 2.0%, driven by declines in the Materials and Information Technology sectors of 7.0% and 1.3%, respectively. As for the longer term, the market has actually risen by 26% in the last year. As for the next few years, earnings are expected to grow by 22% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading